88.26
3.87 (4.59%)
| Previous Close | 84.39 |
| Open | 84.80 |
| Volume | 87,619 |
| Avg. Volume (3M) | 146,049 |
| Market Cap | 625,643,264 |
| Price / Book | 14.87 |
| 52 Weeks Range | |
| Earnings Date | 22 Dec 2025 |
| Diluted EPS (TTM) | -0.400 |
| Total Debt/Equity (MRQ) | 0.30% |
| Current Ratio (MRQ) | 88.27 |
| Operating Cash Flow (TTM) | -4.14 M |
| Levered Free Cash Flow (TTM) | -2.40 M |
| Return on Assets (TTM) | -10.57% |
| Return on Equity (TTM) | -11.21% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Bright Minds Biosciences Inc. | Bearish | - |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 0.38 |
|
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 22.55% |
| % Held by Institutions | 74.12% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Acuta Capital Partners, Llc | 30 Sep 2025 | 84,875 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 25 Nov 2025 | Announcement | Bright Minds Biosciences to Present at Piper Sandler 37th Annual Healthcare Conference and 2025 AES Annual Meeting |
| 17 Nov 2025 | Announcement | Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Experts in Prader-Willi Syndrome (PWS) |
| 06 Nov 2025 | Announcement | Bright Minds Biosciences Initiates New Prader-Willi Syndrome (PWS) Program; KOL Event Scheduled for November 6TH |
| 30 Oct 2025 | Announcement | Bright Minds Biosciences to Present at Upcoming Conferences |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |